Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain
Ancilla W. Fernandes, PhD, David M. Kern, PhD, Catherine Datto, MD, MS, Yen-Wen Chen, PhD, Charles McLeskey, MD, Ozgur Tunceli, PhD
Opioid-induced constipation can adversely affect patients’ quality of life. This study was designed to assess healthcare utilization and costs, including all-cause, constipation-related, and pain-related costs, for patients with versus those without opioid-induced constipation.
Can Improved Management of Opioid-Induced Constipation Mitigate the Associated Costs?
In 2014, the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C raised concerns among the employer community in the United States. The cost implications of these specialty drugs, based on the possibility of their widespread use in patients without advanced disease, had corporate executives hurriedly recalculating their healthcare budgets.
Although the medical and economic burden of heart failure in the United States is already substantial, it will likely grow as the population ages and life expectancy increases
Validating the Impact of Heart Failure Through the Law of Large Numbers
Chronic myelogenous leukemia (CML) is a hematologic cancer that occurs primarily in adults. Although CML can occur at any age, the median age at diagnosis is 64 years, and the incidence increases with age.
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
Thomas J. Van Hoof, MD, EdD, Lisa G. Harrison, MSN, Nicole E. Miller, BS, Maryanne S. Pappas, MS, Michael A. Fischer, MD, MS
An important study by RAND Corporation showed problems in the overall quality of care (patients received only 55% of recommended services among 439 quality measures) as well as variability of care (quality of medical services ranging from 10% to 79% depending on medical condition).
Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease
Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD
Although varicose veins are considered by some policymakers to primarily be an aesthetic concern, varicosities and their resulting sequelae are primary contributors to the morbidity associated with chronic venous diseases.
A Teachable Moment in Health Benefits Design
Margaret K. Pasqule, PhD, Anthony M. Louder, PhD, RPh, Raymond Y. Cheung, PhD, Andrew T. Reiners, MD, Robert J. Sanchez, PhD, Veerainder Goli, MD, MBA, DFAPA, Jack Mardekian, PhD
From 1999 to 2008, the utilization rate of total knee replacement procedures in the United States more than doubled for the overall population, and tripled for individuals aged 45 to 64 years.
Knee and Hip Pain: Rewarding Optimal Long-Term Management
Janice M.S. Lopez, PharmD, MPH, Brian Macomson, PharmD, Varun Ektare, MPH, Dipen Patel, PhD, Marc Botteman, MSc
The Impact of HbA1c Testing on Total Annual Healthcare Expenditures Among Newly Diagnosed Patients with Diabetes
Page 3 of 12
Results 21 - 30 of 111
Results 21 - 30 of 111